Compare Stocks → The A.I. story nobody is telling you (Read ASAP) (From TradeSmith) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:LXRXNYSE:MNKNASDAQ:NBSENASDAQ:OPTNNASDAQ:SBBP Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeLXRXLexicon Pharmaceuticals$1.60-0.6%$2.28$0.92▼$3.79$396.44M1.273.07 million shs1.76 million shsMNKMallinckrodt$0.12$0.34$0.75▼$6.42$1.58MN/A2.62 million shs39,227 shsNBSENeuBase Therapeutics$0.42$0.69$0.39▼$4.80$1.58M0.83111,076 shs21,218 shsOPTNOptiNose$0.93-4.1%$1.48$0.86▼$2.10$109.01M-0.24474,725 shs571,324 shsSBBPStrongbridge Biopharma$2.00$2.09$1.85▼$4.26$135.66M1.58866,464 shs684,684 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceLXRXLexicon Pharmaceuticals-0.62%-1.23%-24.53%-10.11%-32.20%MNKMallinckrodt0.00%0.00%0.00%0.00%-97.99%NBSENeuBase Therapeutics0.00%+0.26%-57.44%-32.12%-83.97%OPTNOptiNose-4.38%-9.28%-38.31%-36.62%-47.72%SBBPStrongbridge Biopharma0.00%0.00%0.00%0.00%0.00%Thousands of investors use this no cost solution | Do you? (Ad)In today’s volatile markets we are all looking for the edge. But imagine tapping into a world where every investment move has the potential to be ahead of the curve. Most investors have heard of the publication Insider Financial. For nearly a decade, they've unlocked doors to opportunities tucked away from the public eye, guiding over a million investors with well researched information before it hits the mainstream media.Simply tap here now to subscribe and start getting "Insider Financial Advantage"MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationLXRXLexicon Pharmaceuticals0.9637 of 5 stars3.01.00.00.01.71.70.6MNKMallinckrodtN/AN/AN/AN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AOPTNOptiNose3.7753 of 5 stars3.53.00.04.20.02.50.6SBBPStrongbridge BiopharmaN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceLXRXLexicon Pharmaceuticals2.00Hold$5.00212.50% UpsideMNKMallinckrodtN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AOPTNOptiNose3.00Buy$4.00332.29% UpsideSBBPStrongbridge BiopharmaN/AN/AN/AN/ACurrent Analyst RatingsLatest LXRX, MNK, NBSE, SBBP, and OPTN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/23/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold4/11/2024LXRXLexicon PharmaceuticalsNeedham & Company LLCSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold3/18/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$5.003/18/2024OPTNOptiNoseLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$3.00 ➝ $4.003/11/2024OPTNOptiNoseHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy$5.00(Data available from 4/25/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookLXRXLexicon Pharmaceuticals$1.20M328.32N/AN/A$0.38 per share4.21MNKMallinckrodtN/AN/AN/AN/A$47.48 per shareN/ANBSENeuBase TherapeuticsN/AN/AN/AN/A$11.04 per shareN/AOPTNOptiNose$70.99M1.47N/AN/A($0.77) per share-1.20SBBPStrongbridge Biopharma$30.73M4.41N/AN/A$0.98 per share2.04Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateLXRXLexicon Pharmaceuticals-$177.12M-$0.80N/AN/AN/A-14,573.20%-138.54%-71.29%5/7/2024 (Estimated)MNKMallinckrodtN/A-$116.19N/A∞N/A-82.59%20.32%2.49%N/ANBSENeuBase Therapeutics-$4.37M-$7.70N/A∞N/AN/A-99.74%-60.13%5/9/2024 (Estimated)OPTNOptiNose-$35.48M-$0.32N/AN/AN/A-50.06%N/A-33.05%5/9/2024 (Estimated)SBBPStrongbridge Biopharma-$45.08M-$0.78N/AN/AN/A-115.67%-66.82%-36.21%N/ALatest LXRX, MNK, NBSE, SBBP, and OPTN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/11/2024Q4 2023LXRXLexicon Pharmaceuticals-$0.23-$0.20+$0.03-$0.20$0.68 million$0.70 million3/7/202412/31/2023OPTNOptiNose-$0.10-$0.09+$0.01-$0.09$19.90 million$19.87 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthLXRXLexicon PharmaceuticalsN/AN/AN/AN/AN/AMNKMallinckrodtN/AN/AN/AN/AN/ANBSENeuBase TherapeuticsN/AN/AN/AN/AN/AOPTNOptiNoseN/AN/AN/AN/AN/ASBBPStrongbridge BiopharmaN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioLXRXLexicon Pharmaceuticals1.075.605.58MNKMallinckrodt1.180.570.31NBSENeuBase TherapeuticsN/A2.872.87OPTNOptiNoseN/A0.600.55SBBPStrongbridge Biopharma0.383.002.95OwnershipInstitutional OwnershipCompanyInstitutional OwnershipLXRXLexicon Pharmaceuticals74.70%MNKMallinckrodt83.74%NBSENeuBase Therapeutics12.37%OPTNOptiNose85.60%SBBPStrongbridge Biopharma52.03%Insider OwnershipCompanyInsider OwnershipLXRXLexicon Pharmaceuticals6.80%MNKMallinckrodt0.30%NBSENeuBase Therapeutics13.90%OPTNOptiNose2.20%SBBPStrongbridge Biopharma5.10%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableLXRXLexicon Pharmaceuticals285246.24 million229.49 millionOptionableMNKMallinckrodt2,70013.17 million13.13 millionNot OptionableNBSENeuBase Therapeutics373.75 million3.23 millionNot OptionableOPTNOptiNose132112.65 million110.17 millionNot OptionableSBBPStrongbridge Biopharma7267.83 millionN/AOptionableLXRX, MNK, NBSE, SBBP, and OPTN HeadlinesSourceHeadlineRising Investment in Patient Support Drives a Greater Biopharma Focus on Measurementfiercepharma.com - March 5 at 7:51 AMMatinas BioPharma Holdings Inc (MTNB)investing.com - February 10 at 12:33 PMLytix Biopharma As Share Price (LYTIX.OL)lse.co.uk - November 15 at 2:21 AMAmbrx Biopharma Inc AMAMmorningstar.com - November 4 at 7:36 PMBiopharma’s rapid transition to omnichannel marketingpharmaphorum.com - September 11 at 9:18 AMHILS Hillstream BioPharma, Inc.seekingalpha.com - August 19 at 3:55 PMABUS - Arbutus Biopharma Corporationfinance.yahoo.com - July 1 at 12:38 PMThe Nominees for Best Biopharma CEO of 2015 Are...thestreet.com - April 25 at 8:23 AMDay One Biopharma Shares Rise 13% After Positive Topline Results for Tovorafenibmarketwatch.com - January 11 at 9:43 PMBiopharma Soars to the Computational Cloudsgenengnews.com - October 9 at 12:47 PMAccord BioPharma Partners with StoryMD to Deliver Advanced Prostate Cancer Educational Content to Clinicians and Patientsmarkets.businessinsider.com - September 22 at 10:04 AMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by ...apnews.com - September 23 at 5:49 PMStrongbridge Biopharma plc Announces Court Hearing Date to Approve Proposed Acquisition by Xeris Pharmaceuticals, Inc.finance.yahoo.com - September 23 at 5:49 PMPress Release: Xeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmasharecast.com - September 14 at 5:56 PMXeris Pharmaceuticals Stockholders Approve Acquisition of Strongbridge Biopharmastockhouse.com - September 14 at 5:56 PMStrongbridge Biopharma plc Announces Shareholder Approval of Proposed Acquisition by Xeris ...apnews.com - September 9 at 12:31 PMLeading Independent Proxy Advisory Firm ISS Recommends Strongbridge Biopharma plc Shareholders ...apnews.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote "FOR" the Transaction With Xeristmcnet.com - August 31 at 7:54 AMSecond Leading Independent Proxy Advisory Firm Glass Lewis Recommends Strongbridge Biopharma plc Shareholders Vote “FOR” the Transaction With Xerisfinance.yahoo.com - August 31 at 7:54 AMStrongbridge Biopharma plc (NASDAQ: SBBP) Have Dropped -20.16% YTD, What Will Happen Nextmarketingsentinel.com - August 14 at 7:50 AMStrongbridge Biopharma: Q2 Earnings Snapshotsfgate.com - August 5 at 8:43 AMStrongbridge Biopharma plc Reports Second Quarter 2021 Financial Results and Provides Corporate Updatefinance.yahoo.com - August 5 at 8:43 AMStrongbridge Biopharma plc Announces Commencement of Mailing of Proxy Statementfinance.yahoo.com - August 2 at 9:34 AMStrongbridge Biopharma plc (NASDAQ:SBBP) Shares Plunges -8.08% In A Week – But Can It Keep Rising?marketingsentinel.com - July 31 at 9:50 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsLexicon PharmaceuticalsNASDAQ:LXRXLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.MallinckrodtNYSE:MNKMallinckrodt Plc is a global specialty pharmaceuticals company. It develops, manufactures, markets and distributes both branded and generic specialty pharmaceutical products and medical imaging agents. It operates through the Specialty Brands and Specialty Generics segments. The Specialty Brands segment includes branded medicines. The Specialty Generics segment relates to specialty generic drugs, active pharmaceutical ingredients, as well as external manufacturing. The company was founded by Gustavo Mallinckrodt, Otto Mallinckrodt and Edward Mallinckrodt in 1867 and is headquartered in Blanchardstown, Dublin.NeuBase TherapeuticsNASDAQ:NBSENeuBase Therapeutics, Inc., a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications. Its pipeline includes NT0100 for Huntington's disease; NT0200 for myotonic dystrophy type 1; and NT0300 treatment targets the mutated KRAS gene. NeuBase Therapeutics, Inc. is headquartered in Pittsburgh, Pennsylvania.OptiNoseNASDAQ:OPTNOptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, throat, and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary exhalation delivery system (EDS) that delivers a topically acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps, as well as is in Phase IIIb clinical trial for treatment of chronic sinusitis; and Onzetra Xsail, a powder EDS device. It has a license agreement with Currax Pharmaceuticals LLC for the commercialization of Onzetra Xsail. The company was founded in 2000 and is headquartered in Yardley, Pennsylvania.Strongbridge BiopharmaNASDAQ:SBBPStrongbridge Biopharma Plc operates as a commercial-stage biopharmaceutical company, which focuses on the development and commercialization of therapies for rare diseases. Its pipeline is comprised of Keveyis, Macrilen, Recorlev, and Veldoreotide. The company was founded in 1996 and is headquartered in Trevose, PA. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.